All In Biotech

Drug Trial Radar · NCT05685173

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

107

Planned (sponsor's estimate)

Start

Apr 20, 2023

Primary completion

Feb 16, 2029

Study completion Jan 13, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)

Conditions

  • B-cell Non-Hodgkins Lymphoma (B-NHL)

Interventions

  • OdronextamabDrug

    Administered per the protocol

  • REGN5837Drug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) of REGN5837 in combination with odronextamabTime frame: From Cycle 2, Day 1 to Cycle 2, Day 21 (each induction cycle is 21 days)
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs) of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years
  3. Severity of TEAEs of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years
  4. Incidence of Adverse Events of Special Interest (AESIs) of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years
  5. Severity of AESIs of REGN5837 in combination with odronextamabTime frame: Up to approximatively 5 years

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • University of California Los Angeles (UCLA) Medical Center

    Santa Monica, California · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Harvard Medical School - Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • NYU Langone Health Perlmutter Cancer Center

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • UT Southwestern

    Dallas, Texas · Recruiting

  • Hopital Saint Louis

    Paris, France · Recruiting

  • Gustave Roussy

    Villejuif, Île-de-France Region, France · Recruiting

  • CHU de Bordeaux

    Talence, New Aquitaine, France · Recruiting

  • Amsterdam University Medical Centre, location AMC

    Amsterdam, Netherlands · Recruiting

  • Erasmus Medical Center Rotterdam

    Rotterdam, South Holland, Netherlands · Recruiting

  • Hospital Vall d'Hebron

    Barcelona, Spain · Recruiting

  • University Hospital and Research Institute

    Madrid, Spain · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital

    Truro, Cornwall, United Kingdom · Recruiting

  • Southampton General Hospital

    Southampton, Hampshire, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, Scotland, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.